Alex Almasan, PhD

Affiliations: 
1995- Cancer Biology The Cleveland Clinic, Cleveland, OH, United States 
Area:
apoptosis, autophagy, DNA repair
Website:
http://www.lerner.ccf.org/cancerbio/almasan/
Google:
"https://scholar.google.com/citations?user=T25Wih4AAAAJ&hl=en&oi=ao"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sharma A, Almasan A. (2020) USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 21
Zhang F, Lou L, Peng B, et al. (2020) Nudix hydrolase NUDT16 regulates 53BP1 protein by reversing 53BP1 ADP-ribosylation. Cancer Research
Kapoor I, Li Y, Sharma A, et al. (2019) Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death & Disease. 10: 924
Sharma A, Alswillah T, Kapoor I, et al. (2019) USP14 is a deubiquitinase for Ku70 and critical determinant of non-homologous end joining repair in autophagy and PTEN-deficient cells. Nucleic Acids Research
La Belle Flynn A, Calhoun BC, Sharma A, et al. (2019) Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature Communications. 10: 3668
Qian M, Almasan A, Gürkan-Çavusoglu E. (2019) Abstract 686: Quantitative analysis of the role of homologous recombination in response to radiotherapy for prostate cancer Cancer Research
Sharma A, Almasan A. (2018) Autophagy as a mechanism of Apo2L/TRAIL resistance. Cancer Biology & Therapy. 1-8
Sharma A, Alswillah T, Singh K, et al. (2018) USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy
Li Y, Kapoor I, Zhu H, et al. (2018) Abstract 2857: PI3K/AKT activation in de novo and acquired resistance to ibrutinib in lymphoid malignancies Cancer Research. 78: 2857-2857
Zhu H, Almasan A. (2017) Development of venetoclax for therapy of lymphoid malignancies. Drug Design, Development and Therapy. 11: 685-694
See more...